RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
RHYTHM PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$88.23+2.06 (+2.39%)
Close on Oct 19, 2026
- Market cap
- $6.05B
- P/E (TTM)
- –
- Dividend yield
- –
RHYTHM PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $239.92M | $217.17M | $194.77M | $179.35M | $161.30M | $141.88M | $130.13M | $112.53M | $101.78M | $91.93M | $77.43M | $61.98M | 100.0% | +48.7% |
| License revenue | $0 | $0 | -$5.01M | – | – | – | – | – | – | – | – | – | 0.0% | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | – | $96.11M | – | – | – | $62.43M | – | – | – |
| Germany | – | – | – | – | – | – | – | – | – | – | $6.08M | – | – | – |
| Other | – | – | – | – | – | – | – | – | – | – | $8.93M | – | – | – |
From the segment and revenue-disaggregation notes of Rhythm Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.